Reneo Pharmaceuticals ( (RPHM) ) has issued an announcement.
Reneo Pharmaceuticals, Inc. is undergoing a significant transformation through a merger with OnKure, Inc., while also halting its historical drug development activities. This strategic shift has led to the termination of Ashley F. Hall, J.D., the Chief Development Officer, effective September 13, 2024. As part of the departure, Hall is set to receive severance benefits as outlined in the company’s existing severance benefit plan.
For detailed information about RPHM stock, go to TipRanks’ Stock Analysis page.
